Neuroendocrine Tumor Treatment Market

The market for Neuroendocrine Tumor Treatment was estimated at $2.4 billion in 2025; it is anticipated to increase to $3.8 billion by 2030, with projections indicating growth to around $5.8 billion by 2035.

Report ID:DS1802006

Author:Debadatta Patel - Senior Consultant

Published Date:January 2025

Datatree

Life Science

Pharmaceutical

Neuroendocrine Tumor Treatment

Customization Available

Neuroendocrine Tumor Treatment - 2025-2035

Market Outlook
Market Key Insights
Growth Opportunity
Market Dynamics
Application
Recent Development
Impact Analysis

Report Summary

Market Data

Methodology

Table of Contents

Report Summary

Market Data

Methodology

Table of Contents

Global Neuroendocrine Tumor Treatment Market Outlook

Revenue, 2025

$2.4B

Forecast, 2035

$5.8B

CAGR, 2026 - 2035

9.1%

The Neuroendocrine Tumor Treatment industry revenue is expected to be around $2.4 billion in 2026 and expected to showcase growth with 9.1% CAGR between 2026 and 2035. The importance of the Neuroendocrine Tumor Treatment industry within global oncology treatments is growing, thanks to a better understanding of the disease, an increase in the diagnosis rate and greater access to treatment options. These are indications for the drug that are primarily of the digestive system and relate to the pancreas, with these in total accounting for 65.3% of the use of the drug. Clinicians now increasingly place a priority on diagnosing these and managing them as per established protocols as early as possible. In 2025, long acting somatostatin analogues generated sales of $1.06 billion, showing the significance of the treatment for controlling the tumour symptoms and disease progression in neuroendocrine cancer. This market continues to be relevant due to investment in precision oncology, the improvement in imaging and pathology facilities and the large number of late stage clinical trials which are currently underway in both emerging and developed healthcare systems. Neuroendocrine tumours are a category of aggressive and rapidly spreading cancerous neuroendocrine tumour marked by a high mitotic rate and poorly differentiated high grade cancerous neuroendocrine tumour.

These cancerous neuroendocrine tumours predominantly appear in the pancreas and the gastrointestinal system and often occur in the lungs and other region's of the body. Across the treatment landscape, these key applications include the use of systemic therapy for neuroendocrine cancers first line and also second line. This systemic therapy is used in patients with tumours of the gastrointestinal tract and the pancreas. Another application of this therapy is in peri operative and palliative care in hospital based and cancer specialist centres, as well as in symptom control. In the sphere of the field, targeted therapies, together with a combination of immunotherapies and peptide receptor radionuclide therapy, are increasingly reshaping the market. Molecular biomarkers and advanced imaging techniques, used in the assessment of response and for staging purposes, are also being routinely integrated. A wide range of trends, including expansion of clinical trials worldwide, the adoption of precision cancer treatments and the use of real life evidence, will increase diversity in the neuroendocrine tumour treatment pipeline. This increased diversity will maintain market demand among pharmaceutical and diagnostic companies.

Neuroendocrine Tumor Treatment market outlook with forecast trends, drivers, opportunities, supply chain, and competition 2025-2035 — Neuroendocrine Tumor Treatment Market Outlook

Market Key Insights

The Neuroendocrine Tumor Treatment market is projected to grow from $2.4 billion in 2025 to $5.8 billion in 2035. This represents a CAGR of 9.1%, reflecting rising demand across Diagnostics and Screening, Therapeutics Development, and Biomedical Research.
In this market there are only seven leading firms, Novartis and Pfizer being the largest. These seven dominate the market.
The U.S. and Germany will have the largest market shares within the neuroendocrine tumour treatment market, these are expected to experience growth at compound annual growth rates of 6.6% to 9.6% between 2025 and 2030.
Growth in emerging markets is expected to be most pronounced in countries such as Brazil, India and South Africa. These countries should achieve a compound annual growth rate of between 8.7% and 11.4%.
Key players in the neuroendocrine tumour market are witnessing a limited adoption rate for surge in the treatment of personalised approaches. This limited adoption has generated a revenue opportunity for chemotherapy and radiotherapy markets which will increase their penetration in hospitals and clinics, eventually capturing $173 million from the neuroendocrine tumour market.
Over the period of 2025 2035, the market for neuroendocrine tumour treatment is expected to reach $3.4 billion. The market segment dealing with clinics and cancer treatment centres is expected to secure the highest share in the neuroendocrine tumour treatment market.
With
rising prevalence of neuroendocrine tumors, and
Advancements in Diagnosis Techniques, Neuroendocrine Tumor Treatment market to expand 139% between 2025 and 2035.

Neuroendocrine Tumor Treatment - Country Share Analysis

Opportunities in the Neuroendocrine Tumor Treatment

Programmes for the Urban Middle Class in Developing Countries to receive a treatment plan tailored to their diagnosis which they can use and be insured for Neuroendocrine Tumours. Growing economies are witnessing an increase in urban middle class patients who are opting for comprehensive treatment plans for neuroendocrine tumours. These plans combine diagnosis, multidisciplinary clinics and treatment methods. Chemotherapy for the treatment of neuroendocrine tumours is also expected to yield greater revenue from $0.45 billion in 2025 to $0.66 billion by the end of 2030. Meanwhile, treatments other than chemotherapy will rise from $0.14 billion to $0.23 billion annually at a rate of 9.95% per annum. Programs combining chemotherapy with radioligand therapy and supportive treatments will be introduced most quickly in major Latin American and Middle Eastern cities.

Growth Opportunities in North America and Asia-Pacific

In North America, the neuroendocrine tumour treatments market is significantly impacted by high adoption rates for targeted therapies for cancer, diagnostic imaging technology and precision medicine for cancer treatment. Pancreatic NEC neuroendocrine tumours are the most strategically significant of this disease, in this region, because the complex nature of the condition and the existence of targeted therapies which are very effective. This rare cancer region offers opportunities for differentiation through treatment algorithms based on biomarkers, for the optimal sequencing of immunotherapy and targeted therapy in advanced cancers of the solid organs, and also for the establishment of centres of excellence that specialise in this disease region. High levels of competition prevail in this region, driven by the pharmaceutical companies established treatments and innovative biotechnology companies that are involved in the study of neuroendocrine tumours. The regions clinical trials infrastructure is strong and genomic profiling is rapidly being integrated into treatment guidelines for neuroendocrine tumours. Additionally payers are increasingly willing to cover high cost treatments which show a survival or quality of life benefit.

Asia Pacific neuroendocrine tumour treatment is dominated by treatment of neuroendocrine cancer of the gut. This is due to the high incidence of gut cancer, improved availability of endoscopy and the increasing availability of laboratories capable of identifying neuroendocrine tumours. The most promising region's of improvement in oncology involve the development of diagnostic techniques which enable cancer to be detected earlier, a more extensive pathology and genetic testing service, and cost effective targeted therapies and injections which can be afforded by local health services. In addition to this, immunotherapy can be used in specific high risk groups. In the field, there is considerable fragmentation, with large multinational companies competing against local generic and biosimilar companies, creating room for new treatments that have clear benefits in the treatment of necrotising enterocolitis and can easily be used by healthcare professionals in a variety of settings. The key drivers for the growth in the neuroendocrine treatment region are the rising healthcare costs, the increasing number of patients with insurance who are able to undergo the oncology treatments, the growing participation in clinical trials and government backing for the upgrading of cancer care infrastructure in the Asia Pacific region.

Market Dynamics and Supply Chain

Driver: Rising Incidence and Early Diagnosis Coupled with Expanding Treatment Modalities

The global neuroendocrine tumor treatment market is also being propelled by two closely linked trends that expand both the patient pool and the therapeutic options available. First, increasing incidence and improved detection through advanced imaging and biomarker technologies have also heightened diagnosis rates of NETs, particularly gastrointestinal and pancreatic forms, allowing clinicians to intervene earlier and expand the treatable population. Enhanced awareness among healthcare providers and patients further fuels demand for treatment. Second, the concurrent expansion of targeted and innovative treatment modalities such as peptide receptor radionuclide therapy, somatostatin analogs, tyrosine kinase inhibitors, and immunotherapeutic approaches is also broadening clinical options beyond traditional chemotherapy. These therapies not only improve efficacy and reduce side effects but also align with personalized medicine trends, prompting wider clinical adoption. Together, these factors strengthen market growth by increasing both the number of diagnosed individuals and the appeal of advanced, tailored treatment regimens.

Sustained investment in R&D and the expansion of clinical trial activity represent a key driver for the neuroendocrine tumor treatment market. Pharmaceutical companies, research institutions, and government agencies are also allocating increased funds toward identifying novel therapeutic targets, advancing radioligand therapies, and validating next-generation somatostatin analogs. This influx of capital accelerates drug discovery and supports the regulatory approval process, fostering a robust innovation pipeline that enhances treatment efficacy and diversifies therapeutic choices. As a result, the market benefits from a continuous introduction of high-precision and personalized treatment options tailored to diverse patient subgroups.

Restraint: High Treatment Costs and Limited Access to Advanced Therapies Restrict Market Adoption

One of the foremost restraints undermining neuroendocrine tumor treatment market growth is the high cost of advanced therapies combined with limited patient access in many regions. Cutting-edge treatments such as PRRT, targeted agents, and long-acting somatostatin analogs are expensive to develop and administer, which increases financial pressure on healthcare systems and patients, especially in low- and middle-income countries. Reimbursement barriers and regional disparities in specialized facilities further hinder adoption, leading to slower uptake and constrained revenue generation for key manufacturers.

Opportunity: Underpenetrated Long-Acting Somatostatin Analogs in Asia-Pacific Neuroendocrine Tumor Care and Targeted Neuroendocrine Tumor Therapies Driving Growth in North American Tertiary Oncology Centers

Growing use of somatostatin analogs in the Asia Pacific region is seen particularly for neuroendocrine tumour treatment within modernising hospitals there. Neuroendocrine tumour treatment in hospitals within Asia Pacific which are rapidly modernising, is in need of improvement when it comes to the delay of disease progression and control of symptoms through the use of long acting somatostatin analogues. This is especially so in India, China and the countries of Southeast Asia. By 2030 the global market for somatostatin analogs will be worth $1.61 billion, from $1.06 billion in 2025. This represents a compound annual growth rate of 8.6%. The increasing availability of medical cover as well as the growth of clinics providing infusion services will, together, boost the demand for injectable treatments which may be stored in a depot. Here, somatostatin analogues will eventually replace chemotherapy, driven by earlier diagnosis, the harmonisation of clinical guidelines and patient centred chronic disease management models.

There is growing use of targeted treatments for neuroendocrine tumors in major North American cancer treatment centers. The treatment of Neuroendocrine Tumors is advancing in North American tertiary hospitals with rapid pace. This is because of biomarker driven therapies, diagnostics which accompany them and the neuroendocrine cancer treatment recommendations which are increasingly widespread. Targeted therapy revenue is forecast to rise to $1.26 billion in the year 2030 from $0.77 billion in 2025 with a compound annual growth rate of 10.4%. There is substantial unexploited potential in the treatment of lung and gastrointestinal neuroendocrine tumours. Advanced imaging procedures, in conjunction with immuno oncology based therapies, do not only get utilised to their fullest capabilities. In this region targeted treatments will be the fastest growing class of therapy, surpassing chemotherapy and others of treatments in growth rate. This is due to growing reimbursement from payers for personalised cancer treatments.

Challenge: Diagnostic Complexity and Limited Awareness Delay Early Detection and Treatment Uptake

The inherent biological heterogeneity of neuroendocrine tumors and low clinician awareness create diagnostic challenges that restrain market expansion. NETs often present with vague or non-specific symptoms, leading to delayed referrals and misclassification, which reduces early treatment opportunities and limits demand for first-line therapies. Without broader educational initiatives and improved access to advanced diagnostic tools, patients are frequently identified at advanced stages, dampening overall treatment utilization and impacting long-term market momentum.

Supply Chain Landscape

Neuroendocrine Tumor Treatment R&D

Novartis AGPfizer Inc

Neuroendocrine Clinical Trials

Hutchison MediPharma LimitedAVEO Pharmaceuticals Inc

Oncology Drug Manufacturing

Ipsen PharmaNovartis AG

Cancer Care Providers

Oncology hospitalsSpecialty clinicsResearch institutes

Neuroendocrine Tumor Treatment R&D

Novartis AGPfizer Inc

Neuroendocrine Clinical Trials

Hutchison MediPharma LimitedAVEO Pharmaceuticals Inc

Oncology Drug Manufacturing

Ipsen PharmaNovartis AG

Cancer Care Providers

Oncology hospitalsSpecialty clinicsResearch institutes

Neuroendocrine Tumor Treatment - Supply Chain

Use Cases of Neuroendocrine Tumor Treatment in Diagnostics & Screening

Diagnostics and Screening : In the neuroendocrine tumor treatment landscape, diagnostics and screening focus on identifying and characterizing tumors early to guide effective management. Somatostatin receptor imaging such as SSTR Positron Emission Tomography and octreotide scans are widely used to detect receptor-positive lesions and assess suitability for targeted therapies. These tools enable precision staging and monitoring, reducing misdiagnosis and enhancing treatment choice. Key players in diagnostics include Thermo Fisher Scientific with FDA-approved assays and imaging reagents, and larger integrated biotech/diagnostics firms like Roche that provide molecular profiling solutions, giving strong clinical accuracy and broad adoption in hospitals and specialty labs globally.

Therapeutics Development : Therapeutics development in the NET market centers on innovative drugs and radioligand therapies that improve survival and quality of life. Somatostatin analogs such as octreotide and lanreotide, targeted agents like everolimus, and peptide receptor radionuclide therapy (PRRT) with ^177Lu-DOTATATE are commonly used in treatment protocols to inhibit tumor growth and deliver targeted radiation. Major pharmaceutical companies leading this space include Novartis AG, Pfizer Inc., and Ipsen Pharma, noted for deep R&D pipelines, regulatory approvals, and strong sales networks. Their strength lies in combining clinical evidence with broad geographic reach, securing leadership in therapeutic portfolios.

Biomedical Research : Biomedical research in NETs drives the discovery of novel molecular targets, biomarkers, and advanced therapies that feed future clinical breakthroughs. Research spans preclinical studies of immunotherapies, CAR-T approaches, and next-generation radiopharmaceuticals supported by foundations like the Neuroendocrine Tumor Research Foundation. Academic centers and biotech firms collaborate to translate these findings into clinical trials, supported by major industry players such as Merck & Co., Eli Lilly, and Novartis. Their investment in precision medicine and translational science accelerates innovation, giving them strong positions in shaping future treatment paradigms.

Recent Developments

Recent developments in neuroendocrine tumor treatment emphasize precision medicine and targeted therapy expansion. Enhanced diagnostic tools such as advanced imaging and genomic profiling improve early detection and personalized care pathways. A key market trend is the rise of peptide receptor radionuclide therapy and somatostatin analogs, boosting clinical adoption and long-term patient outcomes. Biopharma investment in research and clinical trials accelerates next-generation radiopharmaceutical innovation. These shifts strengthen market growth, improve survival rates, and foster integrated oncology solutions across diagnostics and therapeutic platforms.

April 2024 : Novartis’ Lutathera® receives FDA approval for treating pediatric patients with somatostatin receptor-positive gastroenteropancreatic NETs, marking the first pediatric radioligand therapy for this indication.

June 2024 : Ipsen’s expanded collaboration with Exelixis for Cabometyx includes co-development responsibilities and potential regulatory submissions for NET indications beyond the U.S., underscoring strategic expansion efforts.

March 2025 : The U.S. FDA approves CABOMETYX (cabozantinib) for previously treated unresectable or metastatic pancreatic and extra-pancreatic NETs in adults and adolescents 12+ years old, significantly broadening its indication in systemic NET care.

Impact of Industry Transitions on the Neuroendocrine Tumor Treatment Market

As a core segment of the Pharmaceutical industry, the Neuroendocrine Tumor Treatment market develops in line with broader industry shifts. Over recent years, transitions such as Surge in Personalized Treatment Approaches and Advent of Advanced Diagnostic Techniques have redefined priorities across the Pharmaceutical sector, influencing how the Neuroendocrine Tumor Treatment market evolves in terms of demand, applications and competitive dynamics. These transitions highlight the structural changes shaping long-term growth opportunities.

Surge in Personalized Treatment Approaches

Personalised treatments are becoming available for neuroendocrine cancer as genomic and molecular research moves forward. However, the big pharmaceutical companies have been slow to adopt this technology which in turn is having an impact on the market. Presently, conventional chemotherapy and radiotherapy continue to play a significant role in the majority of clinics and hospital oncology services, in spite of the reduced toxicity and superior clinical outcomes that targeted therapies have to offer. This will lead to adjacent and alternative treatments gaining revenue of around $173 million from the neuroendocrine tumour therapy industry. This will result in greater market share and negotiating power for such treatments. This development creates a short term business opportunity for current treatments despite the long term change in Neuroendocrine Tumour Treatment, towards patient treatment on an individual basis.

Advent of Advanced Diagnostic Techniques

The neuroendocrine tumor treatment landscape is undergoing a clear transition driven by advanced diagnostic techniques that are reshaping clinical and adjacent industry workflows. The integration of next generation sequencing, molecular profiling, and somatostatin receptor based imaging has improved tumor classification, origin identification, and therapy selection accuracy. This shift directly supports the growth of precision therapeutics such as targeted drugs and radioligand therapies, increasing demand for companion diagnostics and specialized imaging services. Diagnostic laboratories, radiopharmaceutical manufacturers, and genomics service providers benefit from higher test volumes and premium pricing. At the same time, pharmaceutical developers leverage precise diagnostics to design smaller, biomarker driven clinical trials, reducing development risk and timelines. Collectively, these transitions are strengthening cross industry collaboration between diagnostics, pharma, and nuclear medicine, while gradually improving treatment outcomes and market value realization.